FDA's staff report broke down the trial data by age, gender, race, ethnicity, and more, and its conclusions were extremely encouraging: "[Vaccine efficacy] point estimates were uniformly high across the subgroups examined."
There are two small caveats. The study enrolled only limited numbers of people from certain minority groups, making it impossible to draw statistically significant conclusions. For instance, FDA found the vaccine was 74% effective among Asian study participants—which at a glance might look a lot lower than its 95% effectiveness in the broader population.
https://www.advisory.com/en/daily-briefing/2020/12/11/eua-questions
There are two small caveats. The study enrolled only limited numbers of people from certain minority groups, making it impossible to draw statistically significant conclusions. For instance, FDA found the vaccine was 74% effective among Asian study participants—which at a glance might look a lot lower than its 95% effectiveness in the broader population.
https://www.advisory.com/en/daily-briefing/2020/12/11/eua-questions